Compact Pharmaceutical Manufacture Drug for Efferent Therapy - Enterosorbent ATC07

1. Compact Pharmaceutical Manufacture
Drug for Efferent Therapy
Enterosorbent ATC07
BASOC laboratory
Kyiv City, Ukraine
basoclab@gmail.com
Central Research Laboratory BASOC
Development, Implementation and Production
Drugs for Efferent Therapy

2. Recovery and maintenance
of health requires
elimination of toxins,
pathogens and ballast
substances from the body
Intoxication determines
the severity of the general
human condition and makes
ones feel ill
Human intoxication occurs
with diseases, poisoning,
digestive disorders and
many pathological processes
A serious problem is the
human intoxication
following exogenous and
endogenous poisoning

3. Mission – to provide affordable
and effective drugs for the
treatment of intoxication
Key measures to treat
intoxication is enterosorption
Enterosorption - means
binding and excretion of
endogenous and exogenous
substances, supramolecular
structures and cells from the
gastrointestinal tract
Enterosorbents - drugs for
excretion pathogens
from the gastrointestinal tract
for the treatment and
prevention of diseases

4. 1 gram forms 300 sq.m. of
strongly absorbing surface
Broad-spectrum enterosorbent
АТС07 is based on finely divided
silica
high selective sorption of
protein toxins
does not injure the mucous
membrane of the
gastrointestinal tract (GIT)
allowed for all age categories
no side effects
remove the metabolic
products and pathogens
binds atherogenic
cholesterol
allows to halving the
duration of treatment

5. Prevention and treatment
atherosclerosis
prevention
diarrhea
allergies
alcohol
intoxication
intestinal infections,
dysentery
detoxificationDETOX
food poisoning

6. АТС07SmectaActive-carbon
allergies
peptic ulcer
after radiation
therapy
renal
failure
alcohol
intoxication
chronic hepatitis
food poisoning
diarrhea
dysbacteriosis
intestinal infections
liver cirrhosis

7. Analogs Sales and ProfitabilityPrice
Heilerde,
Myrrhinil,
Lefax
Smecta
Enterosgel,
Polisorbum,
Active-carbon
€ 10-15
$ 3
2 days
$ 450 000
$ 4–8
$ 2–6
50%
1 year
2 M25 g. 150 000
==
300%
АТС07
act. carbon
АТС07
smecta

8. Description enterosorbent АТС07 Description
light powder, white, tasteless,
odorless
Composition
finely divided silica
Pharmachologic effect
enterosorption and detoxification
Substance
the powder is intended for
preparing an oral suspension
Pharmacodynamics
absorbs protein toxins and
pathogens in the lumen of the GIT
Pharmacokinetics
it is not absorbed in the GIT and
excreted in the feces
unchanged

9. Production АТС07 and
raw materials
Competitive advantages of
production of the sorbent ATC07
low cost
simple production
cycle
possibility of production and
delivery small batches
minimum storage
costs of drugs
minimum delivery time to
consumers
minimum shipping
costs
3-5 pers.
380V/50Gz
700 kw
Gegmany
3 м3
200 м2
150 000

10. Technology and documentation of
the sorbent АТС07 production
Quality Control Techniques
Policy brief on enterosorbents use
characteristics of raw materials, semi-finished products
scheme of production space
norms of the raw materials, semi-finished products and energy
hardware scheme of production and equipment specification
technology settings
manuals
industrial safety and environmental protection
general scheme of a quality control system
Production regulations
description of production
Technical specifications1
2
3
4
Р1
Р2
Р3
Р4
Р5
Р7
Р8
Р9
Р6

11. Sorbents consumption in
monetary terms
Sorbents сonsumption in
physical terms
60%
silica-sorbent
active-carbon
$ 125 M
80%
87 million
pack